Importantly, ZD6474 treatment had no impact on the survival of VilCreER;Apcfl/+;KrasG12D/+ mice, highlighting the specificity of this drug for tumours harbouring aberrant activation of TGFβ/ALK5 signalling (Supplementary Fig. 7d). The gene discussed is TGFB1; the disease is neoplasm.